Core Insights - Arvinas, Inc. announced positive results from two Phase 1 clinical trials for ARV-102, an investigational PROTAC degrader targeting LRRK2, showing well-tolerated safety profiles and significant pharmacodynamic effects in both healthy volunteers and Parkinson's disease patients [1][2][5] Group 1: Clinical Trial Results - ARV-102 was well tolerated in clinical trials, with no discontinuations due to adverse events observed [6] - In healthy volunteers, ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure and reduced biomarkers associated with Parkinson's disease after 14 days of treatment [1][6] - In patients with Parkinson's disease, ARV-102 resulted in median reductions of LRRK2 protein of 86% with a 50 mg dose and 97% with a 200 mg dose [6] Group 2: Biomarker and Pharmacodynamic Findings - The treatment led to over 90% reductions of LRRK2 protein in peripheral blood mononuclear cells (PBMCs) and more than 50% reductions in CSF [6] - Significant decreases in lysosomal pathway markers and neuroinflammatory microglial markers were observed in CSF of healthy volunteers treated with ARV-102 [6][9] Group 3: Future Development Plans - Arvinas plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial in patients with Parkinson's disease in 2026 [7] - The company intends to initiate a Phase 1b trial in patients with progressive supranuclear palsy in the first half of 2026, pending data from the multiple dose cohort and investigational new drug clearance [7]

NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform presentation, featuring clinical data for ARV-102, an investigational oral PROTAC (PROteolysis TArgeting Chimera) degrader of leucine-rich repeat kinase 2 (LRRK2), will be presented at the 2025 International Congress of Parkinson ...

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial. ...

Core Insights - Nurix Therapeutics announced the presentation of preclinical data for GS-6791, a novel IRAK4 protein degrader, which supports its advancement into clinical studies [1][2] - The findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress, highlighting the potential of GS-6791 in treating inflammatory diseases [1][4] Preclinical Data - GS-6791 mediates sustained degradation of IRAK4, leading to significant inhibition of IL-1 and IL-36-driven responses in skin epithelial cell systems [2][5] - The drug demonstrated near-complete knockdown of IRAK4 in human blood and keratinocytes, with deep inhibition of cytokine pathways relevant to dermatologic diseases [5] Mechanism of Action - GS-6791 is characterized as a potent, orally available degrader of IRAK4, providing a differentiated pharmacologic profile compared to traditional kinase inhibitors [3][4] - By selectively degrading IRAK4, GS-6791 targets complex immune signaling pathways, potentially expanding treatment options for patients with inflammatory diseases [3][4] Collaboration with Gilead - Nurix and Gilead Sciences entered a strategic collaboration in June 2019 to develop targeted protein degradation therapies, with Nurix receiving $135 million to date [4] - For the IRAK4 program, Nurix is eligible for up to $420 million in potential milestone payments and royalties on net sales, with co-development options available for two programs in the U.S. [4][5] Clinical Development - Gilead exercised its option to license GS-6791 in March 2023, taking responsibility for further development [5] - The Investigational New Drug (IND) application for GS-6791 was cleared by the FDA in April 2025, with an ongoing Phase 1 trial assessing safety and pharmacodynamics in healthy volunteers [5]

Question-and-Answer SessionArthur SandsCEO, President & Director Well, thank you for having us. Happy to give you an introduction. These are our disclaimers. So yes, targeted protein degradation is a new field still, although we've been at it for over 10 years. We're based in San Francisco and the Bay Area based on science out of UCSF and Berkeley. And what's pictured on the slide is this evolution of new therapeutic modalities. So we are in targeted protein degradation, which focuses on the removal of prot ...

Question-and-Answer SessionArthur SandsCEO, President & Director Well, thank you for having us. Happy to give you an introduction. These are our disclaimers. So yes, targeted protein degradation is a new field still, although we've been at it for over 10 years. We're based in San Francisco and the Bay Area based on science out of UCSF and Berkeley. And what's pictured on the slide is this evolution of new therapeutic modalities. So we are in targeted protein degradation, which focuses on the removal of prot ...

Group 1 - The discussion focuses on targeted protein degradation as an evolving therapeutic modality, highlighting its place among successful treatments like antibodies and nucleic acid-based therapies [2][3] - Targeted protein degraders represent a small molecule approach that can effectively remove entire proteins, offering advantages such as oral administration and once-a-day dosing [3][4] - This method is positioned as having antibody-like or biologic-like efficacy, potentially surpassing the effectiveness of traditional nucleic acid-based therapies and antibodies [4]

Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "outlook," "plan," "predict," "should," "will," and ...

Core Insights - C4 Therapeutics, Inc. (C4T) will present data from its Phase 1 clinical trial of cemsidomide for multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025 [1][2] - The company has completed enrollment and dose escalation for the trial, which shows a well-tolerated safety profile and promising response rates [2] - An investor webcast will follow the oral presentation, providing further details on the clinical development plans [3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop new medicines [4] - The company utilizes its TORPEDO platform to design and optimize small-molecule medicines for challenging diseases [4] - C4T's degrader medicines aim to leverage the body's natural protein recycling system to eliminate disease-causing proteins, potentially addressing drug resistance and improving patient outcomes [4] Product Information - Cemsidomide is an investigational small-molecule degrader that targets IKZF1/3, which are transcription factors involved in multiple myeloma and non-Hodgkin's lymphomas [5] - Clinical data indicates that cemsidomide is well-tolerated and shows significant anti-myeloma activity along with immunomodulatory effects [5]

PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 PRT3789 is designed to treat patients with a SMARCA4 mutation. Patients with SMARCA4-mutated cancer, a particularly aggressive form of the disease, have a very poor clinical prognosis. Approximately 10% of all non- small cell lung cancers and 5% of all cancers broadly, harbor a ...